Should Drug Companies Stop Pursuing Amyloid In Treatments For Alzheimer’s?

The pharmaceutical industry has been on a 30 year mission to develop a drug to treat Alzheimer’s disease. The culprits behind the disease, they thought, were the amyloid plaques that build up in the brains of these patients. For many decades removing these plaques to treat Alzheimer’s was the goal.

But then drug after drug targeting amyloid failed to improve the symptoms of Alzheimer’s—the so-called “amyloid hypothesis” wasn’t bearing out. But drug companies kept developing and testing drugs that attacked amyloid from every angle—perhaps at the expense of pursuing other avenues of treatment.

Get one-month FREE access to our online yoga membership site.

Sign up to our mailing list to get one month free (Value $97)

We guard your privacy and will not sell/share your personal information.
We will contact you with information related of things of interest on an occasional basis.
To read our Privacy Policy Click here